Amgen Narrows 340B Purchasing For Neulasta To Enhance Transparency, Firm Says
This article was originally published in The Pink Sheet Daily
An advocacy group representing safety net hospitals has written to Amgen urging the company to withdraw the plan for changing distribution of Neulasta, maintaining it will increase costs and add administrative hurdles.
You may also be interested in...
Policymakers should instead focus on increasing efficiencies in drug development, distribution and reimbursement, National Academies report says, while also seeking broad policies like HHS direct negotiation for drug prices in Medicare.
Senate Finance confirmation hearing concluded without a vote on Xavier Becerra’s nomination as Health and Human Services Department secretary. Republicans continued to express concerns with his background and views. But he is expected to win enough votes to clear the committee.
‘We need the pharmaceutical industry … to always feel we’ve got their back to innovate,’ Becerra tells Senate Committee. ‘But we have to ensure that we’re getting our dollars’ worth.’